| Year |
Citation |
Score |
| 2021 |
Chen HZ, Bonneville R, Paruchuri A, Reeser JW, Wing MR, Samorodnitsky E, Krook MA, Smith AM, Dao T, Miya J, Wang W, Yu L, Freud AG, Allenby P, Cole S, ... ... Roychowdhury S, et al. Genomic and Transcriptomic Characterization of Relapsed SCLC Through Rapid Research Autopsy. Jto Clinical and Research Reports. 2: 100164. PMID 34590014 DOI: 10.1016/j.jtocrr.2021.100164 |
0.574 |
|
| 2020 |
Paruchuri A, Chen HZ, Bonneville R, Reeser JW, Wing MR, Krook MA, Samorodnitsky E, Miya J, Dao T, Smith A, Freud AG, Allenby P, Roychowdhury S. Research Autopsy Demonstrates Polyclonal Acquired Resistance in a Patient With Metastatic GI Stromal Tumor. Jco Precision Oncology. 4. PMID 32923900 DOI: 10.1200/PO.19.00328 |
0.593 |
|
| 2020 |
Makawita S, K Abou-Alfa G, Roychowdhury S, Sadeghi S, Borbath I, Goyal L, Cohn A, Lamarca A, Oh DY, Macarulla T, T Shroff R, Howland M, Li A, Cho T, Pande A, et al. Infigratinib in patients with advanced cholangiocarcinoma with gene fusions/translocations: the PROOF 301 trial. Future Oncology (London, England). PMID 32580579 DOI: 10.2217/Fon-2020-0299 |
0.309 |
|
| 2020 |
Wu C, Williams TM, Robb R, Webb A, Wei L, Chen W, Mikhail S, Ciombor KK, Cardin DB, Timmers C, Krishna SG, Arnold M, Harzman A, Abdel-Misih S, Roychowdhury S, et al. Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32253228 DOI: 10.1158/1078-0432.Ccr-19-4193 |
0.343 |
|
| 2020 |
Brock P, Bustamante Alvarez J, Mortazavi A, Roychowdhury S, Phay J, Khawaja RA, Shah MH, Konda B. Co-occurrence of multiple endocrine neoplasia type 4 and spinal neurofibromatosis: a case report. Familial Cancer. PMID 32052251 DOI: 10.1007/S10689-019-00152-6 |
0.307 |
|
| 2020 |
Krook MA, Lenyo A, Wilberding M, Barker H, Dantuono M, Bailey KM, Chen HZ, Reeser JW, Wing MR, Miya J, Samorodnitsky E, Smith AM, Dao T, Martin DM, Ciombor KK, ... ... Roychowdhury S, et al. Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma. Molecular Cancer Therapeutics. PMID 31911531 DOI: 10.1158/1535-7163.Mct-19-0631 |
0.653 |
|
| 2020 |
Bonneville R, Krook MA, Chen HZ, Smith A, Samorodnitsky E, Wing MR, Reeser JW, Roychowdhury S. Detection of Microsatellite Instability Biomarkers via Next-Generation Sequencing. Methods in Molecular Biology (Clifton, N.J.). 2055: 119-132. PMID 31502149 DOI: 10.1007/978-1-4939-9773-2_5 |
0.315 |
|
| 2020 |
Noonan AM, Lustberg MB, Schnell P, Hays JL, Jin N, Abushahin LI, Malalur PG, Roychowdhury S, Elkhatib RT, Chen H, Mutar SA, Sparreboom A, Hu S. A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with metastatic colorectal cancer receiving FOLFOX chemotherapy and bevacizumab. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps12125 |
0.321 |
|
| 2020 |
Krook MA, Silverman IM, Murugesan K, Ernst G, Reeser J, Wing M, Frampton GM, Newton RC, Jackson JR, Albacker LA, Burn T, Roychowdhury S. Pan-cancer analysis of FGFR1-3 genomic alterations to reveal a complex molecular landscape. Journal of Clinical Oncology. 38: 3620-3620. DOI: 10.1200/Jco.2020.38.15_Suppl.3620 |
0.351 |
|
| 2020 |
Drake CG, Johnson ML, Spira AI, Manji GA, Carbone DP, Henick BS, Ingham M, Liao C, Roychowdhury S, Kyi C, Basciano PA, Bournazou E, Abhyankar J, Bezawada A, Kounavouth S, et al. Personalized viral-based prime/boost immunotherapy targeting patient-specific or shared neoantigens: Immunogenicity, safety, and efficacy results from two ongoing phase I studies. Journal of Clinical Oncology. 38: 3137-3137. DOI: 10.1200/Jco.2020.38.15_Suppl.3137 |
0.327 |
|
| 2019 |
Krook MA, Bonneville R, Chen HZ, Reeser JW, Wing MR, Martin DM, Smith AM, Dao T, Samorodnitsky E, Paruchuri A, Miya J, Baker KR, Yu L, Timmers C, Dittmar K, ... ... Roychowdhury S, et al. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. Cold Spring Harbor Molecular Case Studies. 5. PMID 31371345 DOI: 10.1101/mcs.a004002 |
0.635 |
|
| 2019 |
Krook MA, Barker H, Chen HZ, Reeser JW, Wing MR, Martin D, Smith AM, Dao T, Bonneville R, Samorodnitsky E, Miya J, Freud AG, Monk JP, Clinton SK, Roychowdhury S. Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 31043681 DOI: 10.1038/S41391-019-0145-2 |
0.627 |
|
| 2019 |
Genutis LK, Tomsic J, Bundschuh R, Brock P, Williams MD, Roychowdhury S, Reeser JW, Frankel WL, Alsomali M, Routbort MJ, Broaddus RR, Wakely PE, Phay JE, Walker CJ, de la Chapelle A. Microsatellite Instability Occurs in a Subset of Follicular Thyroid Cancers. Thyroid : Official Journal of the American Thyroid Association. PMID 30747051 DOI: 10.1089/Thy.2018.0655 |
0.331 |
|
| 2019 |
Chen HZ, Bonneville R, Yu L, Wing MR, Reeser JW, Krook MA, Miya J, Samorodnitsky E, Smith A, Martin D, Dao T, Guo Q, Liebner D, Freud AG, Allenby P, ... Roychowdhury S, et al. Genomic characterization of metastatic ultra-hypermutated interdigitating dendritic cell sarcoma through rapid research autopsy. Oncotarget. 10: 277-288. PMID 30719225 DOI: 10.18632/Oncotarget.26352 |
0.673 |
|
| 2019 |
Krook MA, Chen HZ, Bonneville R, Allenby P, Roychowdhury S. Rapid Research Autopsy: Piecing the Puzzle of Tumor Heterogeneity. Trends in Cancer. 5: 1-5. PMID 30616752 DOI: 10.1016/J.Trecan.2018.11.004 |
0.403 |
|
| 2019 |
Chen H, Bonneville R, Krook MA, Wing MR, Reeser JW, Miya J, Paruchuri A, Samorodnitsky E, Yu L, Smith AM, Dao T, Martin D, Guo Q, Magenheim H, Freud AG, ... ... Roychowdhury S, et al. Abstract 748: Genomic characterization of recurrent small cell lung cancer through research autopsy reveals clonal diversity and candidate driver of chemoresistance Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-748 |
0.62 |
|
| 2019 |
Krook MA, Bonneville R, Chen H, Reeser JW, Wing MR, Miya J, Smith AM, Paruchuri A, Dao T, Martin DM, Samorodnitsky E, Baker KR, Timmers C, Dittmar K, Cole S, ... ... Roychowdhury S, et al. Abstract 2909: Rapid autopsy of metastatic cholangiocarcinoma demonstrates diverse patterns of clonal heterogeneity Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2909 |
0.567 |
|
| 2019 |
Krook MA, Lenyo AM, Wilberding MJ, Barker HD, Dantuono M, Chen H, Reeser JW, Wing MR, Miya J, Samorodnitsky E, Smith AM, Dao T, Martin DM, Dittmar K, Ciombor KK, ... ... Roychowdhury S, et al. Abstract 335: Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma Cancer Research. 79: 335-335. DOI: 10.1158/1538-7445.Am2019-335 |
0.654 |
|
| 2019 |
Li G, Krook M, Roychowdhury S, Avogadri F, Ye Y, Moran S. Abstract 2206: Anti-tumor activity of infigratinib, a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3, in FGFR fusion-positive cholangiocarcinoma and other solid tumors Cancer Research. 79: 2206-2206. DOI: 10.1158/1538-7445.Am2019-2206 |
0.425 |
|
| 2018 |
Burkart J, Owen D, Shah MH, Abdel-Misih SRZ, Roychowdhury S, Wesolowski R, Haraldsdottir S, Reeser JW, Samorodnitsky E, Smith A, Konda B. Targeting Mutations in High-Grade Neuroendocrine Carcinoma of the Colon. Journal of the National Comprehensive Cancer Network : Jnccn. 16: 1035-1040. PMID 30181415 DOI: 10.6004/Jnccn.2018.7043 |
0.408 |
|
| 2018 |
Chen HZ, Bonneville R, Roychowdhury S. Implementing Precision Cancer Medicine in the Genomic Era. Seminars in Cancer Biology. PMID 29857039 DOI: 10.1016/J.Semcancer.2018.05.009 |
0.386 |
|
| 2017 |
Wing MR, Reeser JW, Smith AM, Reeder M, Martin D, Jewell BM, Datta J, Miya J, Monk JP, Mortazavi A, Otterson GA, Goldberg RM, VanDeusen JB, Cole S, Dittmar K, ... ... Roychowdhury S, et al. Analytic validation and real-time clinical application of an amplicon-based targeted gene panel for advanced cancer. Oncotarget. 8: 75822-75833. PMID 29100271 DOI: 10.18632/Oncotarget.20616 |
0.744 |
|
| 2017 |
Andritsos LA, Grieselhuber NR, Anghelina M, Rogers KA, Roychowdhury S, Reeser JW, Timmers CD, Freud AG, Blachly JS, Lucas DM, Lozanski G, Jones JA, Williams K, Oakes C, Jones D, et al. Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. Leukemia & Lymphoma. 1-4. PMID 28918710 DOI: 10.1080/10428194.2017.1365853 |
0.596 |
|
| 2017 |
Reeser JW, Martin D, Miya J, Kautto EA, Lyon E, Zhu E, Wing MR, Smith A, Reeder M, Samorodnitsky E, Parks H, Naik KR, Gozgit J, Nowacki N, Davies KD, ... ... Roychowdhury S, et al. Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors. The Journal of Molecular Diagnostics : Jmd. PMID 28802831 DOI: 10.1016/J.Jmoldx.2017.05.006 |
0.636 |
|
| 2017 |
Datta J, Damodaran S, Parks H, Ocrainiciuc C, Miya J, Yu L, Gardner EP, Samorodnitsky E, Wing MR, Bhatt D, Hays J, Reeser JW, Roychowdhury S. Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398. Molecular Cancer Therapeutics. PMID 28255027 DOI: 10.1158/1535-7163.Mct-15-1010 |
0.414 |
|
| 2017 |
Wu CS, Williams TM, Wei L, Umar H, Mikhail S, Ciombor KK, Noonan AM, Roychowdhury S, El-Dika SS, Krishna S, Upchurch B, McCarthy ST, Arnold M, Harzman A, Abdel-Misih S, et al. Phase I study of neoadjuvant 5-fluorouracil (5FU) chemoradiation (CRT) and trametinib in patients with locally advanced rectal cancers (LARC). Journal of Clinical Oncology. 35: 685-685. DOI: 10.1200/Jco.2017.35.4_Suppl.685 |
0.343 |
|
| 2017 |
Wu CS, Williams TM, Wei L, Umar H, Mikhail S, Ciombor KK, Chan E, Noonan AM, Roychowdhury S, El-Dika SS, Krishna S, McCarthy ST, Arnold M, Harzman A, Abdel-Misih S, et al. Phase I study of trametinib with neoadjuvant chemoradiation (CRT) in patients with locally advanced rectal cancers (LARC). Journal of Clinical Oncology. 35: 3612-3612. DOI: 10.1200/Jco.2017.35.15_Suppl.3612 |
0.333 |
|
| 2016 |
Kautto EA, Bonneville R, Miya J, Yu L, Krook MA, Reeser JW, Roychowdhury S. Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS. Oncotarget. PMID 27980218 DOI: 10.18632/Oncotarget.13918 |
0.329 |
|
| 2016 |
Ritter DI, Roychowdhury S, Roy A, Rao S, Landrum MJ, Sonkin D, Shekar M, Davis CF, Hart RK, Micheel C, Weaver M, Van Allen EM, Parsons DW, McLeod HL, Watson MS, et al. Somatic cancer variant curation and harmonization through consensus minimum variant level data. Genome Medicine. 8: 117. PMID 27814769 DOI: 10.1186/S13073-016-0367-Z |
0.334 |
|
| 2016 |
Wuthrick EJ, Williams TM, Wei L, Umar H, Savysan A, Mikhail S, Ciombor K, Noonan A, Roychowdhury S, El-Dika S, Krishna S, Upchurch B, Arnold M, Harzman A, Abdel-Misih S, et al. Phase 1 Study of Trametinib and Neoadjuvant Chemoradiation (CRT) in Locally Advanced Rectal Cancer (LARC) with KRAS, BRAF, or NRAS Mutations. International Journal of Radiation Oncology, Biology, Physics. 96: S107-S108. PMID 27675540 DOI: 10.1016/J.Ijrobp.2016.06.264 |
0.307 |
|
| 2016 |
Raymond VM, Gray SW, Roychowdhury S, Joffe S, Chinnaiyan AM, Parsons DW, Plon SE. Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories. Journal of the National Cancer Institute. 108. PMID 26590952 DOI: 10.1093/Jnci/Djv351 |
0.397 |
|
| 2016 |
Wu CS, Williams TM, Wei L, Umar H, Savysan A, Mikhail S, Ciombor KK, Noonan AM, Roychowdhury S, El-Dika SS, Krishna S, Upchurch B, Arnold M, Harzman A, Abdel-Misih S, et al. Phase I study of trametinib and neoadjuvant chemoradiation (CRT) in patients with locally advanced rectal cancers (LARC) that harbor KRAS, BRAF, or NRAS mutations. Journal of Clinical Oncology. 34: e14126-e14126. DOI: 10.1200/Jco.2016.34.15_Suppl.E14126 |
0.34 |
|
| 2016 |
Prensner JR, Mody RJ, Wu Y, Lonigro RJ, Cao X, Roychowdhury S, Vats P, Frank KM, Asangani I, Palanisamy N, Rabah RM, Kunju LP, Everett J, Stoffel EM, Innis JW, et al. Abstract PR07: The landscape of molecular aberrations in pediatric and young adult cancer patients undergoing clinical sequencing for disease management: Novel biological findings from the Peds-MiOncoSeq study Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-Pr07 |
0.429 |
|
| 2015 |
Roychowdhury S, Chinnaiyan AM. Translating cancer genomes and transcriptomes for precision oncology. Ca: a Cancer Journal For Clinicians. PMID 26528881 DOI: 10.3322/Caac.21329 |
0.37 |
|
| 2015 |
Mody RJ, Wu YM, Lonigro RJ, Cao X, Roychowdhury S, Vats P, Frank KM, Prensner JR, Asangani I, Palanisamy N, Dillman JR, Rabah RM, Kunju LP, Everett J, Raymond VM, et al. Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. Jama. 314: 913-25. PMID 26325560 DOI: 10.1001/Jama.2015.10080 |
0.33 |
|
| 2015 |
Damodaran S, Miya J, Kautto E, Zhu E, Samorodnitsky E, Datta J, Reeser JW, Roychowdhury S. Cancer Driver Log (CanDL): Catalog of Potentially Actionable Cancer Mutations. The Journal of Molecular Diagnostics : Jmd. 17: 554-9. PMID 26320871 DOI: 10.1016/J.Jmoldx.2015.05.002 |
0.368 |
|
| 2015 |
Damodaran S, Berger MF, Roychowdhury S. Clinical tumor sequencing: opportunities and challenges for precision cancer medicine. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. 35: e175-82. PMID 25993170 DOI: 10.14694/EdBook_AM.2015.35.e175 |
0.304 |
|
| 2015 |
Damodaran S, Roychowdhury S. Genomics and Precision Cancer Medicine Oral History Review. 11: 145. DOI: 10.17925/Ohr.2015.11.02.145 |
0.312 |
|
| 2014 |
Roychowdhury S, Chinnaiyan AM. Translating genomics for precision cancer medicine. Annual Review of Genomics and Human Genetics. 15: 395-415. PMID 25184532 DOI: 10.1146/Annurev-Genom-090413-025552 |
0.35 |
|
| 2014 |
Parsons DW, Roy A, Plon SE, Roychowdhury S, Chinnaiyan AM. Clinical tumor sequencing: an incidental casualty of the American College of Medical Genetics and Genomics recommendations for reporting of incidental findings. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 2203-5. PMID 24958819 DOI: 10.1200/Jco.2013.54.8917 |
0.338 |
|
| 2013 |
Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, Kalyana-Sundaram S, Wang R, Ning Y, Hodges L, Gursky A, Siddiqui J, Tomlins SA, Roychowdhury S, Pienta KJ, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer Nature Genetics. 45: 1446-1451. PMID 24185510 DOI: 10.1038/Ng.2823 |
0.316 |
|
| 2013 |
Simon R, Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nature Reviews. Drug Discovery. 12: 358-69. PMID 23629504 DOI: 10.1038/Nrd3979 |
0.339 |
|
| 2013 |
Roychowdhury S, Chinnaiyan AM. Advancing precision medicine for prostate cancer through genomics. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1866-73. PMID 23589550 DOI: 10.1200/Jco.2012.45.3662 |
0.349 |
|
| 2013 |
Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, Lonigro RJ, Vats P, Wang R, Lin SF, Cheng AJ, Kunju LP, Siddiqui J, Tomlins SA, Wyngaard P, ... ... Roychowdhury S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discovery. 3: 636-47. PMID 23558953 DOI: 10.1158/2159-8290.Cd-13-0050 |
0.393 |
|
| 2013 |
Robinson DR, Wu YM, Kalyana-Sundaram S, Cao X, Lonigro RJ, Sung YS, Chen CL, Zhang L, Wang R, Su F, Iyer MK, Roychowdhury S, Siddiqui J, Pienta KJ, Kunju LP, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nature Genetics. 45: 180-5. PMID 23313952 DOI: 10.1038/Ng.2509 |
0.365 |
|
| 2013 |
Zhao W, Long S, Burton G, Patterson K, Mohamed N, Villalona M, Otterson G, Roychowdhury S, Shilo K, Gewirtz A. Molecular Profiling by Next-Generation Sequencing in Nonsmall Cell Lung Cancer American Journal of Clinical Pathology. 140. DOI: 10.1093/Ajcp/140.Suppl1.065 |
0.394 |
|
| 2012 |
Roychowdhury S. Cancer genomics meets clinical trials: the challenge ahead. Personalized Medicine. 9: 459-461. PMID 29768773 DOI: 10.2217/Pme.12.50 |
0.4 |
|
| 2011 |
Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, Barrette T, Everett J, Siddiqui J, Kunju LP, Navone N, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Science Translational Medicine. 3: 111ra121. PMID 22133722 DOI: 10.1126/Scitranslmed.3003161 |
0.419 |
|
| 2011 |
Roychowdhury S, Talpaz M. Managing resistance in chronic myeloid leukemia. Blood Reviews. 25: 279-90. PMID 21982419 DOI: 10.1016/J.Blre.2011.09.001 |
0.351 |
|
| 2006 |
Blaser BW, Schwind NR, Karol S, Chang D, Shin S, Roychowdhury S, Becknell B, Ferketich AK, Kusewitt DF, Blazar BR, Caligiuri MA. Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity. Blood. 108: 2463-9. PMID 16757683 DOI: 10.1182/Blood-2006-04-019059 |
0.499 |
|
| 2005 |
Roychowdhury S, Caligiuri MA. Cytokine therapy for cancer: antigen presentation. Cancer Treatment and Research. 123: 249-66. PMID 16211874 DOI: 10.1007/0-387-27545-2_11 |
0.486 |
|
| 2005 |
Roychowdhury S, Blaser BW, Freud AG, Katz K, Bhatt D, Ferketich AK, Bergdall V, Kusewitt D, Baiocchi RA, Caligiuri MA. IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease. Blood. 106: 2433-5. PMID 15976176 DOI: 10.1182/Blood-2005-04-1597 |
0.66 |
|
| 2005 |
Freud AG, Becknell B, Roychowdhury S, Mao HC, Ferketich AK, Nuovo GJ, Hughes TL, Marburger TB, Sung J, Baiocchi RA, Guimond M, Caligiuri MA. A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity. 22: 295-304. PMID 15780987 DOI: 10.1016/J.Immuni.2005.01.013 |
0.662 |
|
| 2005 |
Dierksheide JE, Baiocchi RA, Ferketich AK, Roychowdhury S, Pelletier RP, Eisenbeis CF, Caligiuri MA, VanBuskirk AM. IFN-γ gene polymorphisms associate with development of EBV + lymphoproliferative disease in hu PBL-SCID mice Blood. 105: 1558-1565. PMID 15498860 DOI: 10.1182/Blood-2003-07-2476 |
0.472 |
|
| 2005 |
May KF, Roychowdhury S, Bhatt D, Kocak E, Bai XF, Liu JQ, Ferketich AK, Martin EW, Caligiuri MA, Zheng P, Liu Y. Anti-human CTLA-4 monoclonal antibody promotes T-cell expansion and immunity in a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies. Blood. 105: 1114-20. PMID 15486062 DOI: 10.1182/Blood-2004-07-2561 |
0.464 |
|
| 2005 |
Blaser BW, Roychowdhury S, Kim DJ, Schwind NR, Bhatt D, Yuan W, Kusewitt DF, Ferketich AK, Caligiuri MA, Guimond M. Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease. Blood. 105: 894-901. PMID 15374888 DOI: 10.1182/Blood-2004-05-1687 |
0.485 |
|
| 2004 |
Roychowdhury S, May KF, Tzou KS, Lin T, Bhatt D, Freud AG, Guimond M, Ferketich AK, Liu Y, Caligiuri MA. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2. Cancer Research. 64: 8062-7. PMID 15520217 DOI: 10.1158/0008-5472.Can-04-1860 |
0.686 |
|
| 2004 |
Roychowdhury S, Baiocchi RA, Vourganti S, Bhatt D, Blaser BW, Freud AG, Chou J, Chen CS, Xiao JJ, Parthun M, Chan KK, Eisenbeis CF, Ferketich AK, Grever MR, Chen CS, et al. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder. Journal of the National Cancer Institute. 96: 1447-57. PMID 15467034 DOI: 10.1093/Jnci/Djh271 |
0.638 |
|
| 2004 |
Eisenbeis CF, Grainger A, Fischer B, Baiocchi RA, Carrodeguas L, Roychowdhury S, Chen L, Banks AL, Davis T, Young D, Kelbick N, Stephens J, Byrd JC, Grever MR, Caligiuri MA, et al. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 6101-10. PMID 15447996 DOI: 10.1158/1078-0432.Ccr-04-0525 |
0.501 |
|
| 2004 |
Freud AG, Becknell B, Roychowdhury S, Mao HC, Ferketich AK, Nuovo GJ, Hughes TL, Marburger TB, Sung J, Baiocchi RA, Guimond M, Caligiuri MA. A Novel Human CD34(+) Subset That Constitutively Expresses the High Affinity Interleukin-2 Receptor Traffics to Lymph Nodes and Differentiates into CD56Bright Natural Killer Cells. Blood. 104: 314-314. DOI: 10.1182/Blood.V104.11.314.314 |
0.669 |
|
| 2003 |
Roychowdhury S, Peng R, Baiocchi RA, Bhatt D, Vourganti S, Grecula J, Gupta N, Eisenbeis CF, Nuovo GJ, Yang W, Schmalbrock P, Ferketich A, Moeschberger M, Porcu P, Barth RF, et al. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Research. 63: 965-71. PMID 12615710 |
0.452 |
|
| 2002 |
Porcu P, Eisenbeis CF, Pelletier RP, Davies EA, Baiocchi RA, Roychowdhury S, Vourganti S, Nuovo GJ, Marsh WL, Ferketich AK, Henry ML, Ferguson RM, Caligiuri MA. Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-cell restoration. Blood. 100: 2341-8. PMID 12239141 DOI: 10.1182/Blood-2002-01-0210 |
0.489 |
|
| 2001 |
Baiocchi RA, Ward JS, Carrodeguas L, Eisenbeis CF, Peng R, Roychowdhury S, Vourganti S, Sekula T, O'Brien M, Moeschberger M, Caligiuri MA. GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder. The Journal of Clinical Investigation. 108: 887-94. PMID 11560958 DOI: 10.1172/Jci12932 |
0.521 |
|
| Show low-probability matches. |